Send to printer »

GEN News Highlights : Jan 17, 2007

Cepheid and bioMerieux Partner on Sepsis Test

Cepheid also received the rights to Cepheid’s MRSA patents for further development.

Cepheid and bioMerieux will together develop and commercialize an innovative line of sepsis test products on the GeneXpert® platform.

The product menu comprises both bacterial and fungal identification assays as well a series of genetic markers for antibiotic resistance. There is also the potential for hospital-acquired pneumonia applications. 

Cepheid will be in charge of manufacturing, and bioMerieux will distribute the sepsis assays on an exclusive, worldwide basis.

In addition, bioMerieux has granted Cepheid a nonexclusive, worldwide license under the Hiramatsu patents on methicillin-resistant staphylococcus aureus (MRSA) for all applications. Cepheid will continue to develop, manufacture, and market MRSA products.